{
    "clinical_study": {
        "@rank": "38639", 
        "arm_group": [
            {
                "arm_group_label": "KI1001", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "KI1001(Circadin\u00ae, Prolonged release tablet which contains melatonin) has showed its efficacy\n      to improve sleep quality in over 55 years old primary insomnia patients. This is a 2nd\n      bridging study to investigate the efficacy and safety of KI1001(Circadin\u00ae) in Korean\n      patients."
        }, 
        "brief_title": "Efficacy and Safety of KI1001 in the Treatment of \u2265 55 Years Old Insomnia Patients", 
        "completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "condition": "Sleep Initiation and Maintenance Disorders", 
        "condition_browse": {
            "mesh_term": "Sleep Initiation and Maintenance Disorders"
        }, 
        "detailed_description": {
            "textblock": "This study is conducted using a randomised, double-blind, placebo controlled parallel group\n      design, after a single-blind placebo period. Primary insomnia patients aged over 55 will be\n      screened for entry into the study.\n\n      After placebo run-in period, Patients will enter a 3 weeks double-blind treatment period.\n\n      Primary parameter is quality of sleep, secondary parameters are including getting to sleep,\n      awakening from sleep, behavior following wakefulness, quality of day and night, sleep\n      latency and quality of life."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female and aged \u226555 years\n\n          -  Suffering from primary insomnia according to DSM-IV criteria and for whom this is the\n             consultation complaint\n\n          -  Good anticipated compliance\n\n          -  Written informed consent to participate in the study given by the patient voluntarily\n\n          -  Confirmed diagnosis of primary insomnia by sleep history questionnaire Established\n             baseline pathology\n\n          -  A good compliance during the two-weeks placebo run-in period defined as 70% to 130%\n             of prescribed tablets\n\n          -  Correct use of the Sleep Diary and of the KMLSEQ\n\n        Exclusion Criteria:\n\n          -  According to DSM-IV, subjects belonging to the following groups are excluded :\n             780.59(breathing related sleep disorder); 307.45(circadian thyrhm sleep disorder);\n             307.47(dyssomnia not otherwise specified); 780.XX(sleep disorder due to a general\n             medical condition)\n\n          -  Known or suspected hypersensitivity to exogenous melatonin or melatonin receptor\n             agonists\n\n          -  Known positive serology for human immunodeficiency virus (HIV) I antibodies or HIV II\n             antibodies\n\n          -  Known chronic active viral hepatitis\n\n          -  Drug abuse or history or drug abuse(including alcohol)\n\n          -  History of severe pathology likely to recur during or immediately after the study\n\n          -  History of severe cardiac disorders\n\n          -  History of severe neurological disorders or cerebral neurosurgery\n\n          -  History of severe psychiatric disorders, especially psychosis and depression,\n             sismotherapy\n\n          -  Depression will be assessed by the Raskin scale : a patient with a total score \u2265 6\n             will not be included\n\n          -  Anxiety will be assessed by the Covi scale : a patient with a total score \u2265 6 will\n             not be included\n\n          -  Dementia will be assessed with the Mini Mental State (MMS) : a patient with a score \u2264\n             24 or 26 (depending on the socio-educational level of the patient) will not be\n             included\n\n          -  Neuro-psychiatric pathologies that might interfere with insomnia, patient assessment\n             or study medication\n\n          -  Use of psychotropic treatments for the past 3 months and during the study\n\n          -  Use of benzodiazepines or other hypnotics during preceding two weeks (including all\n             benzodiazepines; zopiclone, zolpidem, zaleplon, barbiturates, buspirone and\n             hydroxyzine)\n\n          -  All hypnotics or treatments used as an hypnotic are not allowed during the study\n\n          -  Severe pain likely to interfere with sleep\n\n          -  Other sleep disorders according to DSM-IV criteria identified by numerical ICD 9\n             code: breathing-related sleep disorder (780.59), circadian rhythm sleep disorder\n             (307.45), dyssomnia not otherwise specified (307.47) and other sleep disorders\n             (780.xx)\n\n          -  Serious diseases that could interfere with patient assessment\n\n          -  Organic pathologies which have not stabilised and that might interfere with sleep,\n             patient assessment or study medication\n\n          -  Intercurrent acute or chronic somatic diseases likely to interact with sleep (for\n             example: chronic pain from any aetiology, benign prostatic hypertrophy likely to\n             require surgery in the coming six months)\n\n          -  Any concomitant documented progressive disease likely to interfere with the conduct\n             of the study\n\n          -  Any medical condition which might interfere with the completion of the study, or\n             which would be adversely affected and thereby increasing the risk for the patient or\n             interfering with patient assessments.\n\n          -  Patients with an excessive consumption of alcohol, coffee or tea\n\n          -  Patients with an irregular lifestyle or life pattern (e.g. shift workers and patients\n             likely to be jet lagged)\n\n          -  Patients with a Body Mass Index above 30 - obesity\n\n          -  Patients who have taken any investigational drug within two months preceding the\n             first dose of the study drug. Investigational drug is defined as any drug for which a\n             marketing authorisation has not been granted in the country where the study was\n             conducted.\n\n          -  Patients receiving concomitant treatment which are not permitted\n\n          -  A positive drug screen (benzodiazepines and opiates) during the initial two week\n             placebo run-in period"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "55 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02087722", 
            "org_study_id": "13-CC-8303"
        }, 
        "intervention": [
            {
                "arm_group_label": "KI1001", 
                "intervention_name": "KI1001", 
                "intervention_type": "Drug", 
                "other_name": "Prolonged release melatonin 2mg"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "Placebo tablets 2mg"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Primary Insomnia", 
        "lastchanged_date": "March 12, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Suwon", 
                        "country": "Korea, Republic of", 
                        "state": "Gyeonggi", 
                        "zip": "442-723"
                    }, 
                    "name": "St. Vincent Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "143-729"
                    }, 
                    "name": "Konkuk University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "134-727"
                    }, 
                    "name": "Kyung Hee University Hospital at Gangdong"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "130-709"
                    }, 
                    "name": "St. Paul's Hospital"
                }
            }
        ], 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Double-blind, Parallel Group, Randomised, Placebo Controlled, Multicenter, Bridging Study of Efficacy and Safety of KI1001 in the Improvement of Sleep Quality in \u2265 55 Years Old Insomnia Patients", 
        "overall_official": [
            {
                "affiliation": "The Catholic University of Korea, St. Vincent Hospital", 
                "last_name": "Seung-Chul Hong, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Konkuk University Medical Center", 
                "last_name": "Doo-Heum Park, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Kyung Hee University Gangdong Hospital", 
                "last_name": "Won-Chul Shin, M.D., Ph.D.", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Catholic University of Korea, St. Paul's Hospital", 
                "last_name": "Kyu-In Jung, M.D.,Ph.D.", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire QOS - Quality of Sleep", 
            "measure": "QOS in KMLSEQ", 
            "safety_issue": "No", 
            "time_frame": "Three weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02087722"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire GTS - Getting to Sleep", 
                "measure": "GTS in KMLSEQ", 
                "safety_issue": "No", 
                "time_frame": "Three weeks"
            }, 
            {
                "description": "KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire AFS - Awakening from Sleep", 
                "measure": "AFS in KMLSEQ", 
                "safety_issue": "No", 
                "time_frame": "Three weeks"
            }, 
            {
                "description": "KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire BFW - Behavior following Wakefulness", 
                "measure": "BFW in LSEQ", 
                "safety_issue": "No", 
                "time_frame": "Three weeks"
            }, 
            {
                "description": "Quality of Day in Patient Diary", 
                "measure": "QOD", 
                "safety_issue": "No", 
                "time_frame": "Three weeks"
            }, 
            {
                "description": "Quality of Night in Patient Diary", 
                "measure": "QON", 
                "safety_issue": "No", 
                "time_frame": "Three weeks"
            }, 
            {
                "description": "WHO-5 Wellbeing Index QOL - Quality of Life", 
                "measure": "QOL", 
                "safety_issue": "No", 
                "time_frame": "Three weeks"
            }, 
            {
                "description": "Pittsburgh Sleep Quality Index", 
                "measure": "PSQI", 
                "safety_issue": "No", 
                "time_frame": "Three weeks"
            }
        ], 
        "source": "Kuhnil Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "collaborator": {
                "agency": "Neurim Pharmaceuticals Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Kuhnil Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}